-
Nov 1, 2024 | 
bmjopen.bmj.com | Mark C. Petrie |Simon Stewart |Bridget Johnston |Muzeyyen Seckin
Most participants were able to describe their breathlessness experience when it started or acute episode occurred. The participants usually described their breathlessness when triggered (by simple activities such as walking a very short distance, climbing stairs or doing any work in their everyday life). I actually do all the housework. Only when I do a lot at work, and also when I lift heavy things. When I use the vacuum cleaner, I get very short of breath, that’s all. I’m out of breath.
-
Oct 25, 2024 | 
onlinelibrary.wiley.com | Paul Foley |Paul Kalra |John Cleland |Mark C. Petrie
Introduction Iron deficiency is common in patients with heart failure and clinical trials suggest that correction with high-dose intravenous (IV) iron improves symptoms and quality of life and reduces the risk of heart failure hospitalization.1-3 There is a theoretical risk that iron supplements might increase the risk or severity of infection.
-
Aug 2, 2024 | 
jacc.org | Subodh Verma |Mark C. Petrie |Barry A. Borlaug |Javed Butler
References1. "Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets". Cardiovasc Res . 2023;118:3434-3450. 2. "Inflammatory mechanisms in heart failure with preserved ejection fraction". Physiology (Bethesda) . 2023;38:0. 3. "Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions". Cardiovasc Res . 2023;118:3536-3555. 4.
-
May 17, 2024 | 
cfrjournal.com | Harriette Van Spall |Mark C. Petrie |Michael R. Zile |Muthiah Vaduganathan
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial. RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure.
-
May 17, 2024 | 
cfrjournal.com | Harriette Van Spall |Mark C. Petrie |Harold Bays
Video Published: Views: 27 Likes: 0 Average (ratings) HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.
-
May 15, 2024 | 
cfrjournal.com | Harriette Van Spall |Harold Bays |Mark C. Petrie |Muthiah Vaduganathan
HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236). RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure.
-
May 7, 2024 | 
onlinelibrary.wiley.com | Jaclyn Carberry |Mark C. Petrie |Matthew Lee |Katriona J.M. Brooksbank
Introduction The widespread utilization of emergency reperfusion therapy and advances in pharmacological secondary prevention have substantially improved survival rates following an acute myocardial infarction (MI).1, 2 However, some patients still develop heart failure in the weeks, months, and years that follow.2 As the development of heart failure is associated with substantial morbidity and mortality, its prevention is an important therapeutic goal.3 The pathological precursor to heart...
-
Apr 7, 2024 | 00469-0/abstract?hss_channel=tw-27013292&dgcid=twitter_organic_trials24_lancet&sz=64)
thelancet.com | Javed Butler |Baylor Scott |Sanjiv Shah |Mark C. Petrie
Summary In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction.
-
Apr 7, 2024 | 00469-0/abstract&sz=64)
thelancet.com | Javed Butler |Baylor Scott |Sanjiv Shah |Mark C. Petrie
Summary In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction.
-
Apr 6, 2024 | 
nejm.org | Mikhail Kosiborod |Mark C. Petrie |Barry A. Borlaug |Javed Butler
AbstractObesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.
